Compare KAI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KAI | SUPN |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 1996 | 2010 |
| Metric | KAI | SUPN |
|---|---|---|
| Price | $323.70 | $52.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $337.50 | $61.60 |
| AVG Volume (30 Days) | 169.5K | ★ 750.5K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,052,248,000.00 | $392,755,000.00 |
| Revenue This Year | $13.28 | $23.19 |
| Revenue Next Year | $4.87 | $17.65 |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $244.87 | $29.16 |
| 52 Week High | $374.20 | $59.68 |
| Indicator | KAI | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 52.29 |
| Support Level | $317.17 | $47.95 |
| Resistance Level | $346.77 | $58.67 |
| Average True Range (ATR) | 17.00 | 2.30 |
| MACD | -1.99 | -0.02 |
| Stochastic Oscillator | 44.68 | 33.88 |
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.